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Abstract Fractional flow reserve (FFR) measured during in-
vasive coronary angiography is an independent prognosticator
in patients with coronary artery disease and the gold standard
for decision making in coronary revascularization. The inte-
gration of computational fluid dynamics and quantitative an-
atomic and physiologic modeling now enables simulation of
patient-specific hemodynamic parameters including blood ve-
locity, pressure, pressure gradients, and FFR from standard
acquired coronary computed tomography (CT) datasets. In
this review article, we describe the potential impact on clinical
practice and the science behind noninvasive coronary comput-
ed tomography (CT) angiography derived fractional flow re-
serve (FFRCT) as well as future applications of this technology
in treatment planning and quantifying forces on atherosclerot-
ic plaques.
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Abbreviations
APS Axial plaque stress
CAD Coronary artery disease
CTA Computed tomography angiography
CTP Computed tomography perfusion
FFR Fractional flow reserve
FFRCT Fractional flow reserve derived from coronary
computed tomography angiography
ICA Invasive coronary angiography
NPV Negative predictive value
PPV Positive predictive value
WSS Wall shear stress
Introduction
Coronary computed tomography angiography (CTA) is well
established as the noninvasive standard for anatomic assess-
ment of coronary artery disease (CAD) [1, 2]. With improve-
ments in spatial and temporal resolution, both mechanical and
software-based, as well as implementation of large detector
scanners the field of coronary CTA has seen progressive im-
provements over the last 10 years [3–5]. In addition to image
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quality improvements, multiple scanner advances in both im-
age acquisition and reconstruction have enabled coronary
CTA to be performed consistently with radiation dose expo-
sure in the 1–5 mSv range [6–8]. Despite the rapid technology
progression, resting coronary CTA remains a strictly anatomic
test and, as such, similar to conventional invasive angiography
(ICA), it lacks the necessary data to guide revascularization
decisionmaking, whichmandates objective evidence of ische-
mia [9, 10]. Accordingly, the recent “Outcomes of Anatomic
vs Functional testing for Coronary Artery Disease”
(PROMISE) trial, compared coronary CTAwith frontline non-
invasive ischemia testing and demonstrated an almost 50 %
increase in downstream referrals to ICA and a doubling in
coronary revascularization rate which, however, did not trans-
late into improved outcomes [11••]. These findings emphasize
the need of accurate noninvasive gatekeeping to the catheter-
ization laboratory beyond anatomic assessment. The latter gap
in noninvasive diagnostic testing may be addressed through a
strategy combining anatomic and functional data [12]. The
introduction of pharmacologic stress CT perfusion has result-
ed in significant interest with strong early results compared
with both noninvasive and invasive measures of ischemia [4,
13]. Although a promising technique, CT perfusion requires
the administration of a pharmacologic stress agent and a repeat
CT acquisition, thereby increasing both the time required and
the radiation exposure to the patient. Furthermore, CT perfu-
sion provides data analogous to coronary flow reserve, which
has known limitations in isolating epicardial coronary disease
that is treatable with revascularization frommicrovascular dis-
ease without any established therapy. Fractional flow reserve
(FFR) as measured during ICA is broadly recognized as the
gold standard for the discrimination of lesion-specific ische-
mia. FFR, which assesses the ratio of flow across a stenosis to
putative flow in the absence of stenosis, is strongly associated
to the clinical outcome in a continuous manner [14••]. More-
over, FFR has been shown in multiple randomized trials
to guide revascularization in a cost-effective manner com-
pared with both angiographic-guided revascularization
and medical therapy [15–17]. Although a robust tool for
the adjudication of the hemodynamic significance of a
stenosis, FFR is limited by its invasiveness and cost,
and hence in real-world practice it is used for coronary
revascularization decision-making in a minority of pa-
tients [18, 19]. With recent technological and scientific
advancements, noninvasive methods to calculate FFR
have been developed. The integration of computational
fluid dynamics and quantitative anatomic and physiologic
modeling now enables simulation of patient-specific he-
modynamic parameters including blood velocity, pressure,
pressure gradients, and FFR from standard acquired coro-
nary CT datasets [20••]. We herein describe the science
behind, clinical evidence supporting, and future applica-
tions related to coronary CTA derived FFR (FFRCT).
Coronary CTAngiography Derived FFR (FFRCT)
Science and Diagnostic Performance
FFR can be derived from coronary CTA image data acquired
using standard acquisition protocols without the need for ad-
ditional imaging, medication, or radiation. FFRCT analysis
uses mathematical models of blood flow derived from
patient-specific data extracted from coronary CTA images
and solved on high-performance computers. Any mathemati-
cal model of blood flow in the circulation includes at least 3
elements: first, a description of the anatomic region of interest;
second, the mathematical “governing equations” enumerating
the physical laws of blood flow within the region of interest;
and third, “boundary conditions” to define physiologic rela-
tionships between variables at the boundaries of the region of
interest [21]. Although the anatomic region of interest and the
boundary conditions are unique to each patient and the spe-
cific vascular territory, the governing equations describing ve-
locity and pressure are universal and apply in different patients
and other arterial beds. The extraction of the patient-specific
anatomic model from image data is performed using image
processing algorithms [22, 23]. The basic physiologic princi-
ples behind FFRCT have previously been described in detail
[20••]. The first principle is that the total coronary blood
flow (which is proportional to the myocardial oxygen
demand) at rest can be quantified from the myocardial
mass as assessed by CT. The second principle is that the
microcirculatory vascular resistance at rest is inversely
proportional to the size of the coronary arteries supplying
the myocardium, and thus the caliber of both healthy and
diseased vessels adapt to the amount of flow they carry.
The third principle states that the vasodilatory response
of the coronary microcirculation to adenosine infusion is
predictable, allowing computational modeling of the
maximal hyperemic state. Integration of these patient-
specific mathematical models of coronary physiology to
3D computational fluid models enable computation of
coronary flow and pressure at each point in the coronary
tree under hyperemic conditions. Finally, FFRCT is cal-
culated from the ratio of coronary pressure to aortic pres-
sure under simulated maximal hyperemic conditions.
The diagnostic performance of FFRCT in patients with or
suspected stable CAD has been tested in 3 prospective multi-
center trials, the “Diagnosis of Ischemia-Causing Coronary
Stenoses by Noninvasive Fractional Flow Reserve Computed
from Coronary Computed Tomographic Angiograms”
(DISCOVER-FLOW) study [24] the “Determination of Frac-
tional Flow Reserve by Anatomic Computed Tomographic
Angiography” (DeFACTO) study [25••], and the “Analysis
of Coronary Blood Flow Using CTAngiography, Next Steps”
(NXT) [26••] study, respectively. A total of 609 patients and
1050 vessels have been investigated. An overview of study
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design, populations, and estimates of FFRCT diagnostic per-
formance in these 3 trials is presented in Table 1. In all 3 trials,
FFRCT revealed high per-patient and per-vessel discrimination
for the presence of ischemia with blinded comparison to mea-
sured FFR. Moreover, the diagnostic performance of FFRCT
was consistently superior compared with anatomic interpreta-
tion alone. However, in the DeFACTO trial, the prespecified
end-point was not met as the FFRCT accuracy lower limit of
the 95 % confidence interval (67 %–78 %) did not exceed
70 % [25••]. Moreover, although superior to coronary CTA,
the diagnostic specificity of FFRCT in the DeFACTO study
was rather low (42 % for coronary CTA vs 54 % for FFRCT).
However, FFRCT demonstrated higher per-patient and per-
vessel discrimination of ischemia compared with coronary
CTA alone with AUC’s of 0.81 vs 0.68 (P<0.001) and 0.81
vs 0.75 (P < 0.001), respectively [25••]. Of note, the
DeFACTO study was conducted with an early generation
FFRCT analysis algorithm, and use of pre-acquisition beta-
blockers and nitroglycerin was not mandated. Thus, in 25 %
of the vessels assessed, nitroglycerin was not administered,
which may have resulted in underestimation of the coronary
artery diameter with a resultant increase in false positive
FFRCT [27•].Moreover, beta-blockers were not used in almost
one-third of patients, potentially adversely affecting CT image
quality and increasing discordance between FFRCT and FFR
[27•, 28]. The most recent and largest study, the NXT trial
incorporated learnings from the previous 2 trials, including
use of the latest generation of FFRCT analysis software [26••,
29]. In the NXT trial, the per-patient diagnostic accuracy of
FFRCT in predicting lesion-specific ischemia was superior to
anatomic assessment by coronary CTA, 81 % vs 53 %
(P<0.001) arising from an increase in specificity from 34 %
to 79 % (P<0.001). Notably, the NXT trial cohort pre-test
probability of significant CAD was in the intermediate range,
thus representing patients in whom noninvasive imaging is
recommended [30]. The improved diagnostic performance
of FFRCT in the NXT trial compared with the DeFACTO trial
reflects substantial refinements in FFRCT technology and
physiologic modeling, as well as increased focus on coronary
CTA image quality, in particular, regarding heart rate control
and the use of nitroglycerin [27•, 29]. Accordingly, prelimi-
nary data indicate that employing the “NXT” FFRCT compu-
tation technology and standardized CT image metrics on the
DeFACTO CT data set, results in comparable diagnostic
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All studies were prospective. In all studies diagnostic performance and discrimination of lesion specific ischemia (FFR ≤ 0.80) was higher for FFRCT
(≤0.80) than for anatomic assessment by coronary CTA (lumen reduction >50 %) in vessels with a diameter >2 mm
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performance of FFRCT as in the NXT trial [31]. In the NXT
trial, there was a good direct correlation of FFRCT to
invasively measured FFR (r=0.82), with a slight underesti-
mation of FFRCT (mean difference, 0.03) compared with FFR.
The reproducibility of repeated FFRCT calculations are high
with a coefficient of variation between 1.4 % and 4.6 % [32].
Patient examples illustrating the clinical utility of FFRCT in
patients with coronary lesions with or without ischemia is
shown in Figs. 1 and 2.
FFRCT Diagnostic Performance in Specific
Subpopulations
FFRCT has high diagnostic performance in the presence of
coronary calcification (Fig. 1) [33]. In a NXT trial substudy
including 214 patients (333 vessels), there was no difference
in diagnostic accuracy, sensitivity, or specificity of FFRCT
across Agatston score quartiles, including the highest quartile
of patients with Agatston scores ranging between 416 and
3599 [33]. In vessels with the highest Agatston scores, FFRCT
showed significant improved discrimination of ischemia com-
pared with coronary CTA alone (0.91 vs 0.71, P=0.004),
corresponding to 60 % correct reclassification of cases when
moving from coronary CTA to FFRCT. The apparent robust-
ness of FFRCT in the event of coronary calcification is most
likely a result of the FFRCT computation process, including
information on the global coronary and myocardial anatomy
[33]. In contrast, coronary CTA stenosis assessment relies on
identification of segmental changes with resultant reduction in
lumen interpretability and, for this reason, the presence of
artifacts may have a greater impact on interpretation.
In a recent substudy from the NXT trial of vessels with
serial multiple lesions (n = 18), FFRCT values were co-
registered with measured FFR across the lesions, and trans-
lesional differences between FFRCT and FFR were compared
[34]. The mean values of the most distal FFR and FFRCT in
the same regions were 0.72±0.10 and 0.69±0.11, wheeas
FFR and FFRCTwere ≤0.80 in 13 and 14 vessels, respectively.
The coefficient of correlation between trans-lesional delta
FFR and FFRCT in each segment was excellent (0.92,
P<0.001).
The diagnostic performance of FFRCT has been studied
only in patients suspected of stable CAD, and thus the gener-
alizability of FFRCT to other patient categories is currently
unknown. These patients include those with left ventricular
hypertrophy, diabetes, previous myocardial infarction, or pa-
tients with coronary stents or by-pass grafts.
Comparison to Conventional Ischemia Testing Modalities
Current guidelines recommend noninvasive functional imag-
ing testing (eg, stress echocardiography, single photon emis-
sion computed tomography, or cardiac magnetic resonance) as
the first line diagnostic strategy in patients suspected of CAD
[30]. In meta-analyses, using ICA stenosis severity as the ref-
erence standard, noninvasive functional testing has shown
high diagnostic performance for detection or exclusion of ob-
structive CAD [30]. However, when these diagnostic tests are
evaluated using measured FFR rather than ICA stenosis as the
reference standard, diagnostic performance diminishes [35].
Most published studies utilizing FFR as the reference standard
were small and single center-based, and in many of these
studies FFR was often not measured in all vessels, with FFR
values assigned to vessels (and vascular perfusion territories)
on the basis of the angiographic findings in a significant pro-
portion of patients (vessels) [35]. This strategy may lead to
Fig. 1 Case example 1. A 66-year-old manwas referred for evaluation of
atypical chest pain. a, Coronary CTA showed extensive coronary
calcification (Agatston score = 1509) and significant coronary artery
stenosis could not be excluded in either of the major coronary arteries.
b, FFRCTwas 0.64, 0.70, and 0.74 in the left anterior descending (LAD),
the circumflex (Cx), and the right (RCA) coronary arteries, respectively.
c, Invasive coronary angiography showed stenoses (arrows) in the mid-
LAD, Cx, and the RCA, with measured FFR in LAD and Cx being 0,62
and 0.61, respectively. FFR interrogation in RCA was not technically
possible. The patient was treated successfully with coronary artery
bypass grafting. FFRCT= coronary computed tomography angiography
derived fractional flow reserve
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misadjudication since patients with stenosis severity >50 % or
even >70 % often have FFR values >0.80 [9, 10, 36–38],
whereas patients with <50 % stenosis may have FFR
values≤ 0.80 [36–39]. Hitherto no studies have compared
head-to-head the diagnostic performance of conventional non-
invasive functional testing modalities vs FFRCT using FFR as
the reference standard.
Clinical Utility, Cost Effectiveness, and Quality of Life
In the context of rising global healthcare costs, greater atten-
tion is focused on cost-effectiveness of procedures. The field
of noninvasive diagnostic testing comprises a bewildering ar-
ray of test choices often resulting in 2 separate tests for assess-
ment of coronary anatomy and ischemia [30]. Despite the
extensive use of noninvasive testing, ICA continues to play
a major role in the assessment of patients suspected of CAD.
As a result of inaccurate diagnostic discrimination associated
with the use of current noninvasive testing modalities, 60% or
more of patients referred for ICA on a suspicion of CAD do
not have obstructive disease [40], and the majority of patients
having revascularization performed do not have evidence of
ischemia [41]. Moreover, patients with a positive ischemia
testing result are only slightly more likely to have obstructive
CAD at ICA than those who do not undergo testing [42].
Resource utilization and clinical outcome related to the
clinical use of FFRCT in symptomatic patients with suspected
CAD have been evaluated in the prospective, multicenter
“Prospective Longitudinal Trial of FFRCT: Outcome and Re-
source impacts” (PLATFORM) trial [43••]. This study exam-
ined the clinical effectiveness impact of a strategy using
FFRCT to guide management compared with the usual testing
strategy in 11 European centers. A total of 584 patients (mean
age 61 years, 40 % women) with new-onset chest pain, no
prior history of CAD, and an intermediate pre-test likelihood
of obstructive CAD were enrolled. Patients referred for non-
invasive testing were enrolled in a separate stratum than pa-
tients referred for invasive testing. Each stratum was further
subdivided into usual care or FFRCT-guided care. The primary
endpoint was the rate of finding no obstructive stenosis among
those with planned ICA, as defined by ≥50 % in any coronary
artery by quantitative coronary angiography (QCA, core lab-
oratory measurement) or invasive FFR<0.80. Secondary end-
points included clinical outcomes, downstream testing and
treatment, resource utilization, and quality of life measures
[43••]. Study results showed high rates of finding no obstruc-
tive CAD by ICA in both the planned noninvasive and
planned ICA groups. In the planned ICA group, 73 % of usual
care patients had no obstructive CAD compared with only
12 % of patients guided by FFRCT, an 83 % reduction
(P<0.0001). Although clinicians in the PLATFORM study
were not protocol-driven to utilize FFRCT test results, in
61 % of patients with planned ICA, the angiogram was can-
celled after receiving FFRCT results. Nonetheless, there was
no difference in coronary revascularization rates (32 % in
usual care and 29 % in FFRCT, P=ns) and there was a 90 %
increase in the number of patients with both functional and
anatomic information prior to revascularization. Among pa-
tients intended for noninvasive testing, there was no difference
in the rate of finding no obstructive CAD at ICA between
usual care (6 %) and FFRCT (13 %, P=0.95). There were no
adverse clinical events among patients in whom ICAwas can-
celled on the basis of FFRCT, and there was no difference in
clinical outcome between the usual care and FFRCT-guided
groups at 90 days. The latter findings are in accordance with
a recent single-center real-world study comprising 185 con-
secutive patients with stable CAD and intermediate range cor-
onary lesions showing a favorable 12-month follow-up clini-
cal outcome in patients with FFRCT>0.80 (69 % of the study
cohort) being deferred from ICA [44•].
Fig. 2 Case example 2. A 67-year-old female was referred for evaluation
of atypical chest pain. a, Coronary CTA showed minimal coronary
calcification (Agatston score = 8) and a 60 % coronary artery stenosis in
the right coronary artery (RCA) (arrow). b, FFRCT distally in the RCA
was 0.91. c, Invasive coronary angiography showed a 60% stenosis in the
RCA (arrow) with measured FFR distally of 0.93. The patient was treated
successfully with medication. FFRCT= coronary computed tomography
angiography derived fractional flow reserve
Curr Cardiovasc Imaging Rep (2016) 9: 2 Page 5 of 12 2
Simulation analyses based on historic data indicate that
FFRCT guidance for selection of ICA and decision-making
on coronary revascularization may reduce costs in stable
CAD [45, 46]. The effects of using FFRCT instead of usual
care on costs and quality of life (QOL) in the PLATFORM
study have been recently published [47••]. Total medical costs
were derived from the number of diagnostic tests, invasive
procedures, hospitalizations, and medications during 90-day
follow-up multiplied by summedUS cost weights. Changes in
QOL were assessed using the Seattle Angina Questionnaire,
the EuroQOL, and a visual analog scale. Among patients with
planned ICA, mean costs were 32 % lower among the FFRCT
group than among the usual care group ($7343 vs $10,734,
P<0.0001). Among patients with planned noninvasive test-
ing, mean costs were not significantly different between the
FFRCT group and the usual care group ($2679 vs $2137,
P=0.26). Each of the QOL scores improved in the overall
study population (P<0.0001). At 90 days, in the planned
noninvasive testing stratum, QOL scores were significantly
higher in FFRCT patients than in usual care patients, whereas
in the planned ICA stratum the improvements in QOL were
similar in the FFRCT and usual care patients.
FFRCT Testing and Interpretation in Clinical Practice
No current guidelines provide recommendations about the
clinical use of FFRCT testing and its interpretation. As the first
line cohort, we recommend FFRCT testing to be applied in
patients with intermediate range lesions in whom coronary
CTA interpretation is most challenging [9], and where guide-
lines recommend additional ischemia testing to be performed
[30]. This is in accord with previous trial evidence showing
high and superior diagnostic performance of FFRCTcompared
with stenosis assessment by coronary CTA in intermediate
lesions [24, 25••, 26••, 48]. It is well known that a coronary
stenosis with FFR≤0.75 in general causes ischemia, whereas
stenoses with FFR>0.80 are almost never associated with
exercise induced ischemia [49]. Accordingly, an FFR interpre-
tation “grey-zone” ranging between 0.75 and 0.80 has been
introduced in whichmeasures other than FFR are recommend-
ed to be taken into account for decision making on revascu-
larization [49]. Previous studies assessing the diagnostic per-
formance of FFRCT used a binary outcome based on a thresh-
old of 0.80 [24, 25••, 26••]. However, as for FFR, a “black and
white” decision-making based on a specific FFRCT threshold
may not always fit into the reality of clinical practice. Accord-
ingly, in the most recent NXT trial, despite diagnostic superi-
ority compared with coronary CTA stenosis assessment alone,
the FFRCT per-patient specificity and positive predictive value
in predicting ischemia was modest (79 % and 65 %, respec-
tively), and thus a substantial rate of false-positive results
remained [26••]. In line with these findings, the aforemen-
tioned real-world study showed that only 55 % of lesions with
FFRCT ranging between 0.75 and 0.80 caused ischemia using
FFR (threshold, 0.80) as the reference standard, whereas is-
chemia was documented in 92 % of lesions when FFRCTwas
≤0.75 [44•]. On the other hand, prognosis was favorable in
patients being deferred from ICA on the basis of a normal
FFRCT result [44•]. Based on our current knowledge regarding
FFRCT diagnostic performance, and the fact that the overall
prognosis in contemporary practice of stable CAD is favorable
[11••, 43••, 44•], we recommend in patients (vessels) with
FFRCT>0.80 or ≤0.75 a dichotomous interpretation strategy,
whereas in patients with FFRCT ranging between 0.75 and
0.80, decisions on referral to ICA (and decision-making on
coronary revascularization) should be based on all available
information, in particular regarding severity of angina, which
is the main target of PCI (Table 2). The clinical value and
safety of this FFRCT interpretation approach needs delineation
in future studies.
Limitations of FFRCT Testing
Although no special imaging protocols are required for
FFRCT assessment, significant CT imaging artifacts such
as motion, low contrast, or blooming from coronary calcifi-
cation may impair the diagnostic performance of coronary
CTA and thus of FFRCT. In the DeFACTO and NXT trials,
11 % and 13 % of the patients had nonevaluable coronary
CTA images [25••, 26••]. In contrast, in the aforementioned
real-world report of consecutive patients having FFRCT per-
formed, only 2 % of the patients failed to meet the image
quality requirements for FFRCT analysis, and in the total
cohort comprising more than 1200 patients referred for cor-
onary CTA, a conclusive CT-based anatomic or anatomic-
physiological result was available in >90 % [44•]. Issues of
CT uninterpretability can be minimized by adhering to cor-
onary CTA image acquisition guidelines, particularly by
administration of heart-rate lowering medication and sub-
lingual nitrates before image acquisition [27•, 28, 44•, 50].
Table 2 Potential FFRCT interpretation approach
FFRCT result
a Downstream diagnostic work-up
>0.80 No additional testing, OMTb
0.75–0.80 Ambulatory follow-up, OMTb
≤0.75 ICA, OMTb
FFRCT coronary computed tomography angiography derived fractional
flow reserve, ICA invasive coronary angiography, OMT optimal medical
treatment
a Patients with new onset chest pain without known CAD with interme-
diate range coronary artery stenosis determined by coronary CTA
b In general statin, aspirin, and antianginal medication
The “Aarhus FFRCT decision-rule model” (adapted from Nørgaard et al.
[44•])
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Although it has been shown that FFRCT seems to provide
significant diagnostic improvement compared with coro-
nary CTA even at lower levels of coronary CTA image qual-
ity [51], noncompliance with societal guidelines on best
coronary CTA acquisition practice [50] is associated with
impaired FFRCT diagnostic performance [27•]. In the
DeFACTO trial, administration of a pre-scan beta-blocker
increased FFRCT diagnostic specificity from 51 % to 66 %
(P= 0.03), whereas nitroglycerin pretreatment within 30mi-
nutes of CT was associated with improved specificity from
54 % to 75 % (P= 0.01).
Currently, FFRCT testing requires offsite computer pro-
cessing requiring 2–6 hours. However, significantly faster
FFRCT-testing processing times resulting from software
improvements are expected in the near future. Concerns
on the perceived loss of control of local assessment and
the current processing time associated with FFRCT testing
have driven renewed interest in past generations of re-
duced order computational fluid modeling versions that
are less computationally intense and when coupled with
less comprehensive anatomic modeling enables on-site
analysis with reduced analysis times, but an unknown
impact on diagnostic performance. Thus, while noninva-
sive on-site and fast (<1 hour) CT-derived FFR has shown
interesting results in small, single-center, retrospective
studies [52, 53], further investigations in prospective mul-
ticenter trials are needed in order to determine the actual
diagnostic performance of this technique [54]. The relative
long-term prognosis and cost-efficiency of FFRCT testing
compared with conventional ischemia testing modalities is
not known, but studies are ongoing. In the Computed Tomo-
gRaphic Evaluation of Atherosclerotic Determinants of Myo-
cardial IsChEmia (CREDENCE) trial (ClinicalTrials.gov
Identifier:NCT02173275), which is a prospective, multicen-
ter, cross-sectional study of patients scheduled to undergo
clinically indicated nonemergent ICA, the diagnostic perfor-
mance of FFRCT vs myocardial imaging perfusion assessment
(SPECT, positron emission tomography and magnetic reso-
nance myocardial imaging) is compared using FFR as the
reference standard.
Future Applications of Coronary CTA Derived
Computational Fluid Dynamic Modeling
Predicting Outcomes of Cardiovascular Interventions
A particular strength of the computational methods used
to derive FFRCT lies in the possibility of altering the pa-
tient anatomic or physiological model to predict the antic-
ipated benefit of treatments. The potential use of this tech-
nology for planning PCI procedures was explored in a
pilot study including 44 patients who had coronary CT
and FFRCT before catheterization and measured FFR be-
fore and after PCI [55]. FFRCT was performed in a
blinded fashion prior to and after virtual stenting of the
lesions treated invasively. The diagnostic accuracy of
FFRCT to predict ischemia (FFR≤ 0.8) after stenting was
96 %. Further developments in predicting the potential
benefit of alternate revascularization strategies are on the
horizon.
Quantifying Biomechanical Forces Acting on Blood
Vessels
There are a variety of different biomechanical forces that
act on blood vessels arising from internal pressure and
flow and external tissue support. These applied forces
result in stress acting on the surface or within blood ves-
sels, where stress is defined as force per unit area. In
addition to external applied forces, blood vessels have
intrinsic, or residual, stresses emanating from growth
and remodeling [56]. These residual stresses are present
even in the absence of external applied forces. An exam-
ple of a residual stress manifests when a vessel is
transected and retracts or shortens due to the longitudinal
tension in the vessel wall. A detailed discussion of all of
the intrinsic and extrinsic forces and stresses in blood
vessels is beyond the scope of this review, and herein
we focus on forces resulting from internal flow and pres-
sure acting on blood vessels and atherosclerotic plaques.
Wall shear stress (WSS) is defined as the tangential force
per unit area acting on the luminal surface. Axial plaque
stress (APS) is defined as the axial component of the
hemodynamic stress acting on stenotic lesions [57•].
APS and WSS both result from hemodynamic forces act-
ing on the luminal surface, but have important differences.
APS is strongly related to the absolute pressure on the
surface of the plaque, whereas WSS is independent of
the absolute pressure but closely coupled to flow and
the pressure-gradient. APS is much larger than WSS (ie,
approximately 40 times larger than the maximum WSS
even in tight stenoses and under hyperemic conditions
where WSS is maximal [57•]). Both WSS and APS can
be derived from the velocity and pressure fields calculated
by patient-specific modeling of coronary blood flow de-
rived from CT data. Image-based computational methods
have been used to compute wall shear stress noninvasive-
ly in the human abdominal aorta [58, 59], the extracranial
and intracranial cerebral arteries [60–63], and the pulmo-
nary arteries [64, 65].
Plaque Initiation and Progression
WSS plays a role in maintaining endothelial function
and is likely to influence plaque initiation and
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progression [66–69]. WSS is the product of the blood
viscosity and the gradient of the velocity field at the
luminal surface. WSS is sensed by the endothelium
and in turn influences normal endothelial function, as
well as atherosclerosis localization and progression.
Image-based modeling techniques have also been used
to evaluate wall shear stress in the human coronary ar-
teries based on invasive data [70–74], and to a lesser
extent using noninvasive data [75, 76]. The future appli-
cation of image-based modeling derived from CT data
holds great promise for understanding the relationship
between WSS and CAD.
Plaque Evolution, Destabilization, and Rupture
Whereas the mechanical influence of WSS is confined to a
narrow zone of the vessel wall near the endothelium, APS
acts throughout the entire thickness of the plaque and, as
such, is likely to play a more direct role in plaque rupture.
In a recent publication, Choi et al. described the potential
role of APS in plaque rupture and its relationship with
lesion geometry [57•]. APS was found to uniquely charac-
terize the stenotic segment and differentiate forces acting
on upstream and downstream segments of a plaque. While
WSS and pressure were consistently higher in upstream
Fig. 3 Case example 3. FFRCT
and APS analysis computed
under simulated hyperemic
conditions performed
retrospectively on coronary CTA
data acquired one year prior to a
subsequent cardiac arrest and
revascularization of a left anterior
descending artery (LAD) lesion.
a, FFRCT analysis indicates a
markedly functionally significant
lesion in the mid-LAD, b,
coronary CTA images reveal a
mixed non-calcified and calcified
plaque, c, APS values are elevated
in the upstream segment of the
lesion, d, APS averaged over the
upstream segment is in the upper
range of values reported by Choi
et al. [57•]. Note that APS is
approximately 50 times higher
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than in downstream segments, APS could be higher at the
downstream than upstream segment in some lesions, thus
potentially explaining why some plaques rupture at the
downstream segments. Figure 3 depicts the FFRCT result
and the APS for a patient experiencing a cardiac arrest, and
primary percutaneous coronary intervention of an occluded
left anterior descending artery lesion occurring 1 year after
a coronary CTA examination. Although coronary CTA
identified a stenotic lesion, a rubidium-82 rest-stress per-
fusion study was deemed normal and the patient was treat-
ed medically [77]. The FFRCT and APS analyses were per-
formed retrospectively (but without any knowledge of the
patient history) based on the coronary CTA data acquired
1 year prior to the myocardial infarction, indicating a very
low FFRCT result and high APS on the segment upstream
of the minimum lumen area [57•]. The utility of FFRCT and
axial plaque stress for predicting plaque rupture are cur-
rently being evaluated in the “Exploring the Mechanism of
the Plaque Rupture in Acute Myocardial Infarction”
(EMERALD) trial (ClinicalTrials.gov ID: NCT02374775).
Conclusions
FFRCT is a novel noninvasive method that uses compu-
tational fluid dynamics for calculation of FFR by using
patient-specific modeling derived from standard acquired
coronary CTA datasets. During the last 5 years, FFRCT
has undergone remarkable advancements in technology,
and its support in the clinical community challenging
conventional coronary CTA and ischemia testing. More-
over, the clinical potential of combining computational
fluid dynamics with CT to derive informantion that
may enable prediction of the outcomes of coronary inter-
ventions or assessment of plaque vulnerability is
emerging.
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